The Oncology Journal Club Episode 4: ASCO 2020 Review 2

Pinterest LinkedIn Tumblr +

The Oncology Podcast, brought to you by, is proud to present the next episode of The Oncology Journal Club.

This week we have our second post ASCO 2020 Review episode, hosted by the brilliant Professor Eva Segelov from Monash University. She is joined by Dr Craig Underhill from Albury-Wodonga and Professor Hans Prenen from Belgium.

This week Eva interviews Professor Michael Hofman about the TheraP trial. Hans gets the ASCO Winners this week, Eva presents her Losers and Craig shares his favourite ‘Weird and Wonderful’ papers from ASCO. We also have a very special guest appearance from a cult ASCO character… (a note to our American listeners, I apologise in advance for the terrible accent and we hope you enjoy listening nonetheless!)

The banter only gets better so once again you are in for an entertaining and engaging episode of The Oncology Journal Club. As ever, the links to all the papers discussed today are available below.

About The Oncology Journal Club

We have taken an old concept and updated it with a new format. In each episode a team of expert contributors will review topical journal papers and studies presented at key meetings to help keep you informed of the latest developments on the go.

With The Oncology Podcast – and The Oncology Journal Club in particular – we are aiming to deliver oncology news differently,” Rachael Babin, Editor-in-Chief, Oncology News.

We hope you enjoy listening and find this a valuable resource. Please let us know what you think!

This Week’s Team:

Professor Eva Segelov

Eva Segelov

Professor Eva Segelov is a Medical Oncologist and is Director of Oncology at Monash University and Monash Health, Melbourne, Victoria, previously Senior Medical Oncologist at St Vincent’s Hospital, St Vincent’s Private Hospital and St Vincent’s Clinic and Associate Professor of Medicine, University of New South Wales.

Eva has an interest in academic clinical trials in GI and breast cancer and has been a member of the AGITG since 2003. She has clinical trials expertise, links with national and international trials groups, and extensive experience with adult medical education.

Professor Hans Prenen

Hans Prenen

Professor Hans Prenen is a medical oncologist and head of the phase 1 – early clinical trials unit at the Antwerp University Hospital in Belgium. He is a member of several scientific organisations, published many scientific oncology papers in prestigious journals and is regularly invited for lectures at national and international meetings.  His interests are clinical trials and translational research with a focus on digestive oncology.


Dr Craig Underhill

Craig Underhill

Dr Craig Underhill completed his Bachelor of Medicine and Surgery in 1987 at Melbourne University. He completed medical oncology training in Melbourne and worked as the Senior Clinical Research Registrar at Guy’s Hospital, London.

In 1998 arrived in Albury-Wodonga and established a medical oncology practice and clinical trials unit which has developed expertise and infrastructure to ensure the initiation of high quality trials. The research Unit lead by Dr Underhill has twice been awarded NSW Premier’s Award for Innovation in Cancer Clinical Trials, the inaugural award in 2009 and then again in 2012.

Dr Underhill chaired a working party that was instrumental in securing $65 million in federal funding for The Albury Wodonga Regional Cancer Centre which opened in September 2016.

Dr Underhill is the VCCC Regional Oncology Lead and advocates for the increased access to clinical trials for regional Victorians and leads the VCCC teletrials program.

Professor Michael Hofman

Michael Hofman

Professor Michael Hofman is a nuclear medicine physician and physician-scientist at the Peter MacCallum Cancer Centre in Melbourne. He previously completed a research fellowship at Guy’s & St Thomas’ in London. He has broad research interest in radiopharmaceuticals for imaging and therapy (theranostics) in conology. This includes neuroendocrine tumours and haematologic applications and more recently has focussed on improving outcomes for men with prostate cancer.

Dr Hofman has a strong track record leading Phase I, II and III clinical trials ranging from first-in-human evaluation of novel radiopharmaceuticals to conducting large mutli-centre randomised clinical trials. In the latter, through his involvement on the scientific committee of the The Australasian Radiopharmaceutical Trials Network (ArtNet), he has established a network of more than 10 centres around Australia with multi-disciplinary expertise culminated in research presented at leading conferences (ESMO, ASCO, EAU) and published in high impact journal such as The Lancet. He has active grants as chief investigator totalling more than $15 million dollars including the Prostate Cancer Foundation (PCF), Movember, Medical Research Future Fund (MRFF), Prostate Cancer Foundation of Australia (PCFA) and the U.S. Department of Defence.

Rachael Babin

Rachael Babin

Rachael Babin is Editor-in-Chief of The Oncology Newsletter and Publisher of For regular oncology updates for healthcare professionals, please subscribe to The Oncology Newsletter.

With thanks to Eva Segelov, Craig Underhill, Hans Prenen, Michael Hofman and Graham Knowles.



This Week’s Papers:

Main Papers:

  1. Andre, Thierry et al. Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 study. J Clin Oncol 38: 2020 (suppl; abstr LBA4). Access online here.
  2. Hofman, Michael S et al. TheraP: A randomised phase II trial of 177Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel: Initial results (ANZUP protocol 1603). J Clin Oncol 38: 2020 (suppl; abstr 5500). Access online here.

ASCO 2020 Winners, Losers and Craig’s Weird and Wonderful Abstracts:

Hans’ Winners: 

  1. Shore, Neal D. et al. HERO phase III trial: Results comparing relugolix, an oral GnRH receptor antagonist, versus leuprolide acetate for advanced prostate cancer. J Clin Oncol 38: 2020 (suppl; abstr 5602). Access online here.
  2. Joensuu, Heikki et al. Three versus one year of adjuvant imatinib for high-risk gastrointestinal stromal tumor (GIST): Survival analysis of a randomized trial after 10 years of follow-up. J Clin Oncol 38: 2020 (suppl; abstr 11503). Access online here.
  3. You, Benoit et al. Avelumab in patients with gestational trophoblastic tumors resistant to monochemotherapy: Final outcomes of TROPHIMMUN phase II trial, cohort A. J Clin Oncol 38: 2020 (suppl; abstr LBA6008). Access online here.
  4. Norberg, Scott et al. Safety and clinical activity of gene-engineered T-cell therapy targeting HPV-16 E7 for epithelial cancers. J Clin Oncol 38: 2020 (suppl; abstr 101). Access online here.

Eva’s Losers:

  1. The Lancet Peer Review!
  2. The Virtual Meeting itself and it’s technical problems!
  3. Bilani, Nadeem et al. Surgery at primary and metastatic sites for stage IV breast cancer (BC): A National Cancer Database (NCDB) analysis. J Clin Oncol 38: 2020 (suppl; abstr 1099). Access online here.
  4. Hiester, Andreas. Late toxicities and recurrences in patients with clinical stage I nonseminomatous germ cell tumor after one cycle of adjuvant BEP versus primary retroperitoneal lymph node dissection: A 13-years follow-up analysis of a phase III trial cohort. J Clin Oncol 38: 2020 (suppl; abstr 5512). Access online here.
  5. Garrel, Renaud et al. Equivalence randomized trial comparing treatment based on sentinel node biopsy versus neck dissection in operable T1-T2N0 oral and oropharyngeal cancer. J Clin Oncol 38: 2020 (suppl; abstr 6501). Access online here.
  6. Somashekhar, S. P., et al. CRS + HIPEC in stage IIIc epithelial ovarian cancer and comparison of oncological outcome only with CRS and IV chemotherapy and CRS + IP chemotherapy. J Clin Oncol 38: 2020 (suppl; abstr e18054). Access online here.
  7. Abel, Mary Kathryn et al. The increasing incidence of colorectal cancer in younger patients in the United States: Who, what, when, and where? J Clin Oncol 38: 2020 (suppl; abstr 1573). Access online here.

Craig’s Weird and Wonderful Abstracts:

  1. Worst, Michelle Arielle et al. Optimizing management of glioblastoma: Educational impact on clinicians. J Clin Oncol 38: 2020 (suppl; abstr 11026). Access online here.
  2. Sheng, Jennifer Y., et al. The impact of weight loss on physical function in overweight or obese breast cancer survivors. J Clin Oncol 38: 2020 (suppl; abstr 12053). Access online here.
  3. Madariaga, Ainhoa et al. Phase I/II trial assessing hydroxychloroquine and itraconazole in women with advanced platinum-resistant epithelial ovarian cancer (EOC) (HYDRA-01). J Clin Oncol 38: 2020 (suppl; abstr 6049). Access online here.
  4. Bourlon, Maria Teresa, et al. Global oncology authorship and access patterns. J Clin Oncol 38: 2020 (suppl; abstr 7061). Access online here. 



About Author

ONA Editor

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Leave A Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.